Innovative science is a central component of the CARB-X portfolio.
Find out more about our partners’ projects.
Using patterns to decode a sea of bacteria, the first-in-kind diagnostic identifies bacterial pneumonia and provides definitive antibiotic susceptibility results in 4 hours.
Full Story
SpeeDx and QuantuMDx aim for a first-in-kind diagnostic to rapidly identify bacterial infections and provide a phenotypic result in under 1 hour. The portable, battery-operated device could be used in remote settings and LMICs.
Full Story
Antibiotics are losing effectiveness—and millions are dying as a result. The Brink examines the progress CARB-X has made over six years as it aims to strengthen the pipeline of new products to address this global health threat.
Full Story
How Entasis engineered ETX0462, a novel antibiotic that safely targets top biothreat pathogens
Full Story
Integrated BioTherapeutics’ toxin-targeted Staphylococcus aureus vaccine leverages a decade of hard-earned learnings
Full Story
Lumen's low-cost oral preventative binds and neutralizes Campylobacter jejuni and enterotoxigenic Escherichia coli (ETEC).
Full Story
Vedanta Biosciences’ new VE303 drug will prevent life-threatening C. difficile infections by boosting the body’s microbiome
Full Story
Cellics Therapeutics: Looking at drug development ‘upside down’
Full Story
Drug-resistant bacteria kill 700,000 people each year. The Boston Globe examines whether CARB-X can help solve the crisis.
Full Story
T2’s superbug detector is first product to launch from CARB-X
Full Story
If successful and approved for use in patients, Vaxcyte's (formerly SutroVax) new vaccine could prevent infections, and curb the spread of Group A Streptococcus (GAS) superbugs
Full Story
SciBac is fighting fire with fire by using improved bugs as drugs
Full Story
Vedanta is fighting superbugs by boosting the body's microbiome
Full Story
Bugworks is developing a ‘superdrug’ to treat superbugs
Full Story